- Home
- FIG vs EXEL Comparison
FIG vs EXEL Comparison
Compare FIG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | EXEL |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.7B |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FIG | EXEL |
|---|---|---|
| Price | $27.27 | $56.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $50.50 | $46.50 |
| AVG Volume (30 Days) | ★ 18.6M | 2.6M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.80 | ★ 57.95 |
| EPS | N/A | ★ 1.60 |
| Revenue | ★ $1,055,788,000.00 | $452,477,000.00 |
| Revenue This Year | $31.18 | $13.61 |
| Revenue Next Year | $20.22 | $13.13 |
| P/E Ratio | ★ N/A | $34.09 |
| Revenue Growth | ★ 40.96 | N/A |
| 52 Week Low | $16.60 | $33.76 |
| 52 Week High | $71.41 | $57.57 |
Technical Indicators
Market Signals| Indicator | FIG | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 56.48 |
| Support Level | $26.79 | $54.30 |
| Resistance Level | $28.11 | $57.12 |
| Average True Range (ATR) | 1.55 | 1.56 |
| MACD | 0.10 | 0.29 |
| Stochastic Oscillator | 83.70 | 99.82 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.